Completed PHASE2 INTERVENTIONAL 1-arm NCT00039377

Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051), and Transplantation for Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG

Sponsor: National Cancer Institute (NCI)

Conditions Adult Acute Lymphoblastic Leukemia in Remission

Interventions allogeneic hematopoietic stem cell transplantation autologous hematopoietic stem cell transplantation cyclophosphamide cytarabine etoposide filgrastim imatinib mesylate laboratory biomarker analysis leucovorin calcium methotrexate peripheral blood stem cell transplantation tacrolimus total-body irradiation vincristine sulfate

Updated 7 times since 2017 Last updated: Nov 13, 2014 Started: Apr 30, 2002 Primary completion: Apr 30, 2012 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00039377, this PHASE2 trial focuses on Adult Acute Lymphoblastic Leukemia in Remission and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Bangor, United States , Beverly, United States , Billings, United States , Bloomington, United States , Bozeman, United States , Buffalo, United States , Butte, United States , Canton, United States , Carthage, United States and 54 more locations